



ASX ANNOUNCEMENT

2 April 2019

## **CardieX and inHealth Announce Landmark US Study and Collaboration on Cardiovascular Disease and Telehealth Utilizing AtCor's SphygmoCor® Technology**

### **Highlights**

- CardieX subsidiary AtCor Medical combines its market-leading SphygmoCor® central blood pressure measurement technology in a trial cardiovascular treatment program with leading telehealth business inHealth for a world-first commercial trial assessing a combination solution for superior patient health outcomes.
- inHealth (CardieX subsidiary) will collaborate with two of the most recognised medical and telehealth researchers in the industry, The Pennington Biomedical Research Center at Louisiana State University (the largest obesity research center in the US), and leading research mHealth center, The University of South Carolina.
- Cost of heart failure to US circa US\$30 billion annually with cardiovascular disease costs expected to exceed \$1 trillion by 2035 (Science Daily).
- Data from the Cardiovascular Disease and Telehealth study will be used by inHealth to demonstrate how a combined approach of mHealth devices and telehealth lifestyle counselling for cardiovascular disease can significantly improve patient health outcomes.
- Telehealth is a US\$25B industry in the United States and growing rapidly at a compound rate of 18% per annum. Currently over 50% of hospitals in the US deploy telehealth solutions.
- 3-year study will be supported by funding from the US National Institute of Health (NIH), inHealth is targeting a NIH grant to support the trial with total funding of \$990K. This project is currently in pilot data collection phase.
- As previously announced to the ASX inHealth, Kaiser Permanente, and California State University Long Beach (CSULB) have also combined for one of the largest diabetes lifestyle intervention studies undertaken using inHealth's telehealth services.
- Diabetes is at epidemic proportions with 11-15% of US population living with the disease. Data from the study is to be used by inHealth to further refine and validate inHealth's existing diabetes health programs offered through major healthcare providers.
- The two trials are the first phase of a significant ongoing commercial opportunity for the CardieX Group. Both trials are in progress and are key to assessing the ongoing benefits of telehealth-based patient lifestyle interventions on diabetes and cardiovascular disease management.

For personal use only



- **Kaiser Permanente and inHealth research collaborators California State University Long Beach, Coastal Carolina University, Louisiana State University, and University of South Carolina continue to validate inHealth as a key provider of clinically based healthcare programs.**

**CardieX Limited (ASX: CDX) (CardieX, the Company)** is pleased to announce its group company inHealth Medical Services, Inc ("inHealth") is undertaking a new ground-breaking commercial study and collaboration on cardiovascular disease and telehealth utilising CardieX subsidiary AtCor Medical's ("AtCor") innovative SphygmoCor® technology.

inHealth has secured two highly coveted research collaborators for the world-first commercial trial; The Pennington Biomedical Research Center at Louisiana State University, which is the largest obesity research center in the US - and one of the United States most well-regarded research health centers - and The University of South Carolina. inHealth has also secured top-tier California State University Long Beach (CSULB) and Coastal Carolina University (CCU) to also collaborate on the program.

The study collaborators will also support inHealth's diabetes lifestyle intervention study which demonstrates the clinical importance of telehealth services in the management of chronic disease. As previously announced on 28 November 2018, inHealth, in partnership with one of the largest management healthcare providers in the US, Kaiser Permanente, together with CSULB is undertaking one of the broadest lifestyle intervention studies to date using inHealth's telehealth services and patient lifestyle programs. The study (which is currently underway) aims to determine the effects of lifestyle intervention and telehealth coaching on disease progression, treatment and, management.

inHealth's cardiovascular study is a world first which will investigate how cost-effective telehealth solutions can prevent and improve cardiovascular disease. Currently, cardiovascular disease is the top cause of premature death globally with costs expected to exceed \$1 trillion by 2035. The trial will be the first of its kind to leverage inHealth's telehealth solutions with AtCor's Sphygmocor technology to analyze weight loss and central blood pressure (cBP) changes with telehealth-based lifestyle coaching.

As mentioned above, the trial will utilize AtCor's cutting-edge SphygmoCor® technology which is used clinically for central arterial pressure waveform analysis to better inform blood pressure treatment options. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of intervention, effects which cannot be detected with standard brachial blood pressure measurements.

The technology is the gold standard to measure central blood pressure (cBP) and in combination with inHealth's telehealth services it is anticipated the combined technology and treatment approach will lead to improved patient health outcomes globally.

CardieX's FDA approved SphygmoCor technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals worldwide. In addition, the SphygmoCor® system is used in all of the top 20 hospitals on the US News 2018-2019 best hospitals honor roll ranking.

For personal use only



As announced previously, inHealth is also undertaking a diabetes lifestyle intervention study to assess the ongoing role of patient lifestyle intervention to reduce body weight and support diabetes management. The targeted 7-year study uses inHealth's telehealth nutrition, exercise, and lifestyle telehealth coaching programs and is one of the largest combined diabetes and telemedicine trials to date.

The data and findings from the study will be used to further refine and validate inHealth's existing healthcare programs. Two NIH grants are targeted to support the study with total funding expected to be \$2.8M with inHealth securing telehealth provider/coach, technology, and consulting fees.

**On the two trials and collaboration announcement CardieX CEO, Craig Cooper commented:**

*"These two transformational clinical studies will completely transform the management and treatment of cardiovascular disease and diabetes and will place inHealth's telehealth services firmly at the forefront of modern healthcare. We are moving rapidly forward to create a world leading telehealth company servicing global insurance, corporate, practitioner, and consumer markets. Together with inHealth's partnerships with Anthem, American Well, and the Blue Cross Shield Association of health insurance providers, this new trial, and the support of world leading collaborators, will further position inHealth at the cutting edge of the US healthcare industry."*

**For more information please contact:**

**Chief Executive Officer**  
**Craig Cooper**  
[ccooper@cardiex.com](mailto:ccooper@cardiex.com)

**NWR Communications**  
**Peter Taylor and Anne Leslie**  
[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)  
[anne@nwrcommunications.com.au](mailto:anne@nwrcommunications.com.au)

**About CardieX**

CardieX Limited is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with Telehealth services provider, inHealth Medical Services, Inc, allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

**About inHealth**

inHealth Medical Services Inc, is a leading US provider of Telehealth services, providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care program. inHealth's patient care programs are based on long-term clinical trials that demonstrate superior patient outcomes through the use of Telehealth coaching services. inHealth has partnerships with some of the leading healthcare institutions in the USA including Anthem, American Well and Kaiser Permanente.

For personal use only